Ultragenyx Pharma Posts Smaller Than Expected Q2 Loss, Reaffirms Guidance

  • Ultragenyx Pharmaceutical Inc's RARE Q2 sales reached $89.3 million, up from $86.97 million a year ago, beating the consensus of $87.51 million.
  • The company recognized $64.0 million in Crysvita (burosumab) revenue in the Ultragenyx territories, including $51.6 million in collaboration revenue in the North American profit share territory and net product sales in other territories regions of $12.4 million. 
  • Yoyalty revenue related to European Crysvita sales was $5.4 million. 
  • Dojolvi's (triheptanoin) product sales were $13.5 million. Mepsevii (vestronidase alfa) product sales were $4.9 million.
  • Related: Ultragenyx Sells One-Third Of Future North American Crysvita Royalties For $500M.
  • The company reported an EPS loss of $(2.26), higher than $(1.81) a year ago and better than the consensus of $(1.75).
  • As of June 30, 2022, cash, cash equivalents, and marketable debt securities were $706.1 million.
  • Guidance: The company continues to expect FY22 revenue for Crysvita in Ultragenyx territories of $250 million - $260 million and Dojolvi revenue of $55 million - $65 million.
  • Price Action: RARE shares are up 4.66% at $54.30 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!